46 results about "Joint swelling" patented technology

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a preparation method and application of a medicinal and edible traditional Chinese medicine compound with an effect of treating uric acid diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of semen plantaginis, 15 to 25 parts of pawpaw, 5 to 15 parts of rhizoma smilacis glabrae, 5 to 15 parts of herba portulacae, 1 to 11 parts of radix glycyrrhizae preparata, 5 to 15 parts of folium mori, 5 to 15 parts of folium perillae, 1 to 11 parts of semen pruni, 5 to 15 parts of rhizoma polygonati, 1 to 11 parts of black dates and 1 to 9 parts of mulberries. The traditional Chinese medicine compound is composed of medicinal and edible raw materials, has stable efficacy of reducing uric acid and relieving uric acid liver and kidney injury, renal fibrosis and gouty arthritis, can relieve arthrocele caused by gout, reduces the level of joint inflammatory factors and the like, and takes effect quickly. The traditional Chinese medicine composition can be used for treating hyperuricemia, uric acid nephropathy, gouty arthritis and hyperuricemia accompanying symptoms.

The invention discloses a traditional Chinese medicine liniment for treating rheumatoid arthritis and a preparation process thereof, the traditional Chinese medicine liniment is composed of a wind-dispelling and pain-relieving liquid medicine and auxiliary materials, the wind-dispelling and pain-relieving liquid medicine contains eight traditional Chinese medicines of thorny elaeagnus root, erythrina bark, kadsura longepedunculata root, waxberry root, ardisia crenata, rose mallow root, glabrous sarcandra herb and wikstroemia canescens root, and is prepared by ultrasonic extraction; the auxiliary materials comprise polyvinyl alcohol, a chitosan-acetic acid solution, glycerol, azone, methylparaben, vanillyl butyl ether and ethanol. The liniment is short in film forming time and good in stability, has excellent transdermal absorption performance and antioxidant activity, can remarkably relieve joint swelling of RA model mice, improve the pain threshold value, improve joint pathological injuries, achieve local precise long-acting administration, reduce side effects of the whole body and improve patient compliance, is suitable for clinical treatment of RA, and has a wide application prospect. The problems that an existing rheumatoid arthritis treatment medicine is large in side effect, and a traditional Chinese medicine preparation is short in efficacy duration and inconvenient to use are solved.

The invention belongs to the field of biological medicine, and discloses a chicoric acid (CA)-loaded tetrahedral framework nucleic acid (tFNA) nano preparation for treating acute gouty arthritis. According to the preparation, tFNA formed by self-assembly is taken as a carrier, and a natural active ingredient CA is loaded to form a CA-tFNA compound. The compound overcomes the defects that CA is poor in water solubility and low in bioavailability, and existing drugs are weak in targeting and large in side effect. Through the targeted delivery and synergistic effect of tFNA, the preparation can be effectively enriched in inflammatory joints, significantly inhibit NF-kappa B signal pathways, and down-regulate the expression of key proinflammatory factors such as TNF-alpha and IL-1beta, so that joint swelling and synovial tissue damage are relieved, and repair is promoted. Experiments show that the traditional Chinese medicine composition is remarkable in curative effect and good in safety, and a novel efficient treatment strategy is provided for acute gouty arthritis.

The invention relates to the technical field of arthritis treatment jackets, in particular to a rheumatoid arthritis hand auxiliary treatment jacket which comprises a glove, the glove is divided into a palm face and a hand back face, a wrist is constructed on one side of the glove, and a pressure control piece is arranged on the glove; the pressure control part comprises a cavity constructed in the glove, the cavity divides the glove into an outer layer and an inner layer, the outer layer is made of a heat preservation material, and the inner layer is made of an elastic material; a water injection valve communicated with the cavity is arranged on the glove, and liquid is allowed to enter and exit from the cavity by opening and closing the water injection valve; the three pressure control modes of wrist air bag pressurization and hand movement dynamic pressurization are adjusted through the liquid medicine injection amount, a patient can autonomously select pressure gears according to the illness state and the scene, low-gear mild pressurization is conducted during daily office mild movement, slight aching pain is relieved, operation is not affected, middle-gear moderate pressurization is conducted when joint swelling pain is aggravated, and therefore the patient can feel more comfortable. During night rest, middle and low gears can be flexibly selected, and morning stiffness is relieved while constraint feeling is avoided.

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

The invention belongs to the technical field of medicines. The invention relates to a plaster, in particular to a plaster containing anilinoprofen and a composition. The invention provides an externally applied medicine containing anilinoprofen or a composition containing anilinoprofen and iguratimod. Pharmacodynamic studies show that the aniline-ibuprofen single-prescription plaster can treat osteoarthritis (OA) and rheumatoid arthritis (RA), can effectively inhibit arthrocele and volume increase, remarkably reduces the level of proinflammatory factors, and improves the pathological score of joint tissue. After the anilinoprofen and the iguratimod are combined for use, the curative effect is further enhanced, multiple indexes are obviously superior to those of a single drug group, and an obvious synergistic interaction effect is shown. The iguratimod and anilinoprofen compound preparation disclosed by the invention is developed in an external form such as a gel plaster for the first time, an external compound system of anilinoprofen and iguratimod is innovatively constructed, a safe, effective and convenient novel local treatment choice is provided for OA / RA patients, especially people with oral taboo or needing long-term treatment, and the iguratimod and anilinoprofen compound preparation has good clinical transformation potential and application value.

The invention relates to the technical field of biological medicines, in particular to application of pellicine to preparation of a medicine for treating rheumatoid arthritis. The in-vivo echinaceine can interfere with the pathological process of rheumatoid arthritis in a multi-dimensional manner by inhibiting proliferation, migration and invasion of MH7A cells induced by TNF-alpha, promoting apoptosis of the MH7A cells and down-regulating protein expression of IL-6, MMP-3 and MMP-9. In vivo, the pellicine can relieve joint swelling, synovitis and cartilage injury of adjuvant arthritis rats by inhibiting protein expression of RF, IL-6, MMP-3 and MMP-9. The pellicine has the prospect of being developed into the medicine for treating rheumatoid arthritis.

The invention discloses an application of sanguisorba officinalis sapogenin in preparation of a medicine for treating gout. Compared with the prior art, it is found for the first time that sanguisorba sapogenin can treat gout, especially acute gouty arthritis. Animal research proves that the sanguisorba sapogenin can remarkably relieve joint swelling and tissue damage caused by acute gouty arthritis by inhibiting release of inflammatory factors such as IL-1beta and TNF-alpha. Meanwhile, the sanguisorba sapogenin can also remarkably reduce the level of serum uric acid, and also has a certain treatment effect on gout in a remission stage and a chronic stage. Therefore, the sanguisorba officinalis sapogenin can be used for treating gout and has the potential and prospect of being prepared into the anti-gout medicine.

The invention provides a traditional Chinese medicine composition with an anti-inflammatory effect and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following functional components: oldenlandia diffusa, rhizoma smilacis glabrae, astragalus membranaceus, radix aconiti carmichaeli, sargentgloryvine stem, madder, centipede and liquorice. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-45 parts of oldenlandia diffusa, 30-45 parts of rhizoma smilacis glabrae, 30-45 parts of astragalus membranaceus, 10-15 parts of radix aconiti carmichaeli, 10-20 parts of sargentgloryvine stem, 10-15 parts of madder, 2-4 parts of centipede and 6-9 parts of liquorice through mixing and water extraction, and the components have a synergistic effect, so that the traditional Chinese medicine composition has the effects of detoxifying, expelling toxins and diminishing swelling, has a remarkable effect of treating rheumatoid arthritis and is free of toxic and side effects. The methotrexate pharmaceutical composition has the advantages that the methotrexate pharmaceutical composition has an obvious curative effect on treating joint swelling of a patient, especially has an obvious curative effect on improving joint swelling of a patient, can better reduce inflammation indexes ESR and CRP, has more advantages in long-term curative effects on improving joint pressing pain and joint swelling, and can effectively improve the drug effect of methotrexate and reduce toxic / side effects of methotrexate.

The application discloses application of a medicine composition in preparation of a medicine for treating rheumatoid arthritis (RA), and belongs to the field of RA treating medicines. The medicine composition is composed of swertiamarin (SW) and neochlorogenic acid (NCA) and is screened from two active ingredients in Danteng Yimu Decoction. With the help of animal model and cell model experiments, the action mechanism of the medicine composition in treating RA is explored, the related symptoms and indexes of collagen-induced arthritis (CIA) rats can be effectively improved, joint swelling can be relieved, arthritis inflammation index can be reduced, inflammatory factor release can be inhibited, joint bone quality can be protected, arthritis inflammation infiltration and cartilage destruction can be reduced, and the medicine safety is good. The composition can effectively inhibit the inflammatory factor release and migration ability of rheumatoid arthritis fibroblast-like synoviocytes (RA-FLS). Animal experiments and cell experiments prove that the combination of neochlorogenic acid and swertiamarin (SW+NCA) can be effectively applied to clinical treatment of RA and has a wide application prospect.

The application discloses application of myrtenal in preparation of a medicine for preventing and / or treating rheumatoid arthritis. The application verifies for the first time that myrtenal can block the RA inflammatory cascade from multiple aspects, and overcomes the limitation that single-target treatment is easy to produce drug resistance. Specifically, myrtenal can reduce the levels of inflammatory factors and metal proteins; inhibit the proliferation, migration and invasion of synovial fibroblasts SFs; inhibit the expression of glycolysis-related genes, reduce sugar metabolites; inhibit the synovial tissue hyperplasia, inflammatory cell infiltration, bone erosion and bone destruction of mice joints; promote the mental state of arthritis mice to be obviously improved, the food intake to be increased, the hair to be shiny, the joint swelling to be subsided, the bruise of the ankle joint to be subsided, the skin to be improved, and the activity to be sensitive. Therefore, the application proposes a new medical use of myrtenal in treating rheumatoid arthritis, and develops a brand-new therapeutic indication of myrtenal.

The application discloses application of CPI2 protein in preparation of anti-gouty arthritis drugs and belongs to the technical field of biological medicine. The application discloses the application of the CPI2 protein in preparation of anti-gouty arthritis drugs, and the amino acid sequence of the CPI2 protein is shown as SEQ ID NO. 1. The CPI2 protein disclosed by the application can reduce joint swelling caused by sodium urate, reduce inflammatory cell infiltration, reduce the levels of proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha, increase the level of anti-inflammatory cytokine IL-10, increase the activities of SOD and GSH-Px, and reduce the content of MDA, and can be prepared as a drug for preventing or treating gouty arthritis and has clinical application value.

The invention provides a nursing traditional Chinese medicine external preparation for relieving rheumatic arthralgia, and relates to the technical field of traditional Chinese medicines. On the basis of the theory of traditional Chinese medicine, a traditional Chinese medicine formula composed of pine nodular branch, ormosia henryi, shinyleaf pricklyash root, peach twig, lance asiabell root, arachnoid cyanotis root, dentiferous dendropanax root, rhizoma curculiginis, winter jasmine, wintergreen, folium cortex eucommiae, semen sesami nigrum, fructus viticis, semen allii tuberosi, rhizoma smilacis glabrae and herba menthae is prepared and used for externally treating rheumatoid arthritis in traditional Chinese medicine. The traditional Chinese medicine has the effects of promoting blood circulation to remove meridian obstruction, relieving swelling and pain, dispelling wind and eliminating dampness, tonifying liver and kidney, strengthening muscles and bones, clearing heat and promoting diuresis. The traditional Chinese medicine external preparation disclosed by the invention has excellent anti-inflammatory, detumescence and analgesic effects, has excellent performance in the aspects of improving clinical symptoms such as joint swelling, pain and pressing pain of a patient and improving sleep and joint functions, and takes effect quickly. The traditional Chinese medicine external preparation provides effective nursing means and measures for relieving or relieving rheumatic arthralgia.

The invention relates to the technical field of Tibetan medicine preparations, in particular to a Tibetan medicine composition for treating rheumatoid arthritis and a preparation method. The Tibetan medicine composition is prepared from 18 Tibetan medicines including fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit and the like according to a specific weight ratio, and the monarch, minister, assistant and guide relationship is defined based on the Tibetan medicine true brucellosis theory; according to the preparation method, a low-temperature superfine grinding and step-by-step extraction process is innovatively adopted, three dosage forms of powder, a nano drug-loaded emulsion and a temperature-sensitive acupoint patch are developed, and a dual quality control system of HPLC (High Performance Liquid Chromatography) content determination and fingerprint spectrum is established. TNF-alpha and IL-6 target spots and nf-kb and PI3K-AKT inflammation pathways are synergistically regulated and controlled through multiple components, joint swelling and bone erosion are relieved, and gastrointestinal tract side effects of western medicines are avoided; the transdermal absorption efficiency is improved by a nano drug-loading technology, acupoint targeted drug delivery is realized by the temperature-sensitive patch, and verification shows that the joint swelling inhibition rate is greater than or equal to 70%, the inflammatory factor decrease amplitude is greater than or equal to 50%, and the patch is suitable for patients with mild, moderate and severe rheumatoid arthritis and has a wide clinical application prospect.

This invention discloses the application of PT-129 in the preparation of drugs for treating rheumatoid arthritis (RA), belonging to the field of RA treatment. This invention is the first to demonstrate that the compound PT-129 can target and intervene in the synovial microenvironment, effectively inhibiting the abnormal activation behaviors of RA fibroblast-like synovial cells (FLS) such as proliferation, migration, and invasion, and downregulating the expression of N-cadherin and MMP3 proteins in synovial tissue. This invention provides a combined drug formulation containing PT-129 and RGFP966. This composition exhibits a significant synergistic effect in vivo, effectively relieving joint swelling, increasing bone density and trabecular bone thickness, reducing trabecular bone separation, thereby inhibiting cartilage degradation and bone destruction. This invention provides a novel targeted drug and combination therapy with definite efficacy for the clinical intervention of RA, possessing extremely high clinical application development value.

The mirabilite ice compress bag comprises an inner cold compress bag and an outer cold compress bag, and the inner cold compress bag and the outer cold compress bag are detachably connected to the inner face and the outer face of an assembly bag respectively. An ice compress material in the inner cold compress bag is mirabilite, and the inner cold compress bag is divided into a plurality of rhombic grids; the mirabilite is uniformly distributed in the plurality of diamond grids; the ice compress material in the outer cold compress bag is gel; the assembly bag is slightly larger than the inner cold compress bag and the outer cold compress bag; a wire mesh is embedded in the body; and when the metal wire mesh deforms, the assembly bag is driven to deform. The ice compress bag and the mirabilite are combined for use, so that clinical symptoms of a patient can be improved, functional recovery can be promoted, the hospitalization period can be shortened, the medical cost can be reduced, and the satisfaction degree of the patient can be improved.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.

The application provides application of SEMA3E protein in preparation of a drug for treating rheumatoid arthritis and promoting cartilage regeneration, and belongs to the technical field of biological medicine. The amino acid sequence of the SEMA3E protein is shown as SEQ ID No. 1. Research results show that one month after injection of the SEMA3E protein solution, the joint swelling degree of the double hind limbs of an animal model is reduced, the joint space and integrity are restored to normal, the cartilage thickness is increased, and the phenomenon of synovial cell infiltration and invasion into the cartilage is eliminated. That is, the SEMA3E protein can well reduce joint cavity inflammation and improve damaged joints.

The application discloses a traditional Chinese medicine composition for treating rheumatoid arthritis, a medicine and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine pharmacy. The application aims to relieve joint swelling, inhibit joint bone erosion damage, effectively reduce the concentration of serum proinflammatory factors, and efficiently treat rheumatoid arthritis with damp-heat stagnation syndrome. The traditional Chinese medicine composition is prepared by mixing radix astragali, caulis sinomenii, rhizoma et herba artemisiae scopariae, radix sophorae flavescentis, radix et rhizoma anemarrhenae, radix et rhizoma smilacis glabrae, radix angelicae sinensis, radix paeoniae alba and rhizoma corydalis, and has strict matching of monarch, minister, assistant and messenger, can clear heat and drain dampness, dispel wind and dredge collaterals, tonify qi and nourish blood, activate blood and relieve pain, and has the advantages of treating symptoms and resisting inflammation and detumescence and strengthening the body and protecting bones, and has synergistic effect, is mild in drug property, can be prepared into conventional oral preparations, has simple and stable preparation process, is suitable for industrial production and long-term clinical use, and has good medicinal value and popularization prospect.

The invention belongs to the field of biological medicine or health food, and particularly relates to a composition for improving bone joint health and application thereof. Through wide research, the combination of the chondroitin sulfate sodium with small molecular weight and N-acetylglucosamine achieves unexpected synergistic effects in the aspects of inhibiting inflammatory factor level, improving arthralgia / stiffness, reducing joint swelling, maintaining articular cartilage health and the like; and a foundation is laid for developing products capable of effectively maintaining the health of bone joints.

The application discloses a method for constructing a spontaneous rheumatoid arthritis animal model, and the rheumatoid arthritis phenotype of the mouse is spontaneously generated by knocking out PPARgamma in the skin keratinocytes of the joint part, including joint swelling, joint synovial thickening, inflammatory cell infiltration, anti-cyclic citrullinated polypeptide antibody increase, and rheumatoid factor increase, so that the clinical symptoms of the rheumatoid arthritis are simulated, and an important tool is provided for the related research of the rheumatoid arthritis.

The invention discloses a novel application of a Guangkang capsule medicine. According to the application of the Gukang capsule medicine in preparation of the medicine for treating gout, the medicine for treating gout is a medicine preparation prepared from an extract obtained by mixing and decocting 570 g of roots of Japanese banana, 400 g of creeping oxalis, 600 g of fructus psoraleae and 300 g of radix dipsaci with water, 150 g of pseudo-ginseng fine powder, 30 g of fine powder of the roots of Japanese banana and pharmaceutically acceptable auxiliary materials. Animal experiments show that the serum uric acid level of a hyperuricemia model mouse can be remarkably reduced, and joint swelling and inflammatory cell infiltration are relieved. Clinical observation further proves that the traditional Chinese medicine composition has a good curative effect on improvement of arthralgia, limited activity and other symptoms of gout patients, is relatively high in safety and does not have obvious adverse reaction.

The invention provides a traditional Chinese medicine compound for treating gouty arthritis, and relates to the technical field of traditional Chinese medicine pharmacy. According to the traditional Chinese medicine compound, chicory and clerodendranthus spicatus are used as monarch drugs, rhizoma anemarrhenae is used as ministerial drugs, ramulus mori, pine nodular branch, sophora flower bud, celery seed, cassia twig and radix paeoniae alba are used as adjuvant drugs, and radix fici simplicissimae is used as conductant drugs, so that the whole formula is cold and warm, purgation and tonification are combined, both symptoms and root causes are taken into consideration, and the effects of clearing heat, promoting diuresis, activating meridians to stop pain, tonifying spleen and purging turbidity are achieved. The curative effect of the traditional Chinese medicine compound on treating gouty arthritis is evaluated by constructing a gouty arthritis cell model, and experimental results show that the traditional Chinese medicine compound improves the pathological conditions of joint tissues by reducing the expression level of inflammatory mediators in the joint tissues, so that the curative effect of treating gouty arthritis is improved. The arthrocele degree of GA model rats is well reduced, the condition of joint dysfunction is improved, and the traditional Chinese medicine composition has a remarkable treatment effect on gouty arthritis rats. The traditional Chinese medicine compound is expected to be used as a new medicine for treating gouty arthritis for further research and application.

The application provides a targeted pathological B cell temperature-sensitive hydrogel bone repair material and a preparation method and application thereof, and belongs to the technical field of bone repair biomaterials. The targeted pathological B cell bone repair material HPCH / B3-Cu-Zn-MBGs temperature-sensitive hydrogel provided by the application is prepared by mixing hydroxypropyl chitin HPCH and B3-Cu-Zn-MBGs, and the mass ratio of the hydroxypropyl chitin HPCH and the B3-Cu-Zn-MBGs is 5:1-1:1. The HPCH / B3-Cu-Zn-MBGs provided by the application significantly improves joint swelling, reduces arthritis index, and reduces the clinical symptoms of RA through the comprehensive action thereof.

The invention provides an extract with an acute gouty arthritis relieving effect and application thereof. The medicine is used for treating acute gouty arthritis of mammals. The plantain extract acts on an acute gouty arthritis model rat in a specific intragastric administration mode, the joint swelling degree of the model rat can be remarkably reduced, and inflammatory cell infiltration of synovial tissue is relieved.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicine for gout, which is characterized in that the traditional Chinese medicine composition is prepared from rehmannia root, cistanche, rhizoma cibotii, glossy privet fruit, epimedium, suberect spatholobus stem, radish seed, rhizoma drynariae and radix achyranthis bidentatae. The composition disclosed by the invention can be used for remarkably improving inflammatory response of a gout mouse model; the arthrocele of a mouse gout model caused by MSU and the level of IL-18 and caspase-1 in joint tissues can be obviously reduced. The total cell number, the percentage of neutrophil and the levels of IL-18 and IL-8 in mouse air sac lavage fluid are remarkably reduced, and it is prompted that the traditional Chinese medicine composition can remarkably inhibit the inflammatory reaction induced by MSU and has a good treatment effect on arthritis caused by gout.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. The invention discovers that the nerve cilia protein 2 (NRP2) plays an important role in CHIKV infection SH-SY5Y and U87 cells, and the CHIKV infection can be obviously inhibited by down-regulating the expression of the NRP2. The invention provides an application of NRP2 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.